- Home
- AACT vs AVDL Comparison
AACT vs AVDL Comparison
Compare AACT & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACT
- AVDL
- Stock Information
- Founded
- AACT 2021
- AVDL 2015
- Country
- AACT United States
- AVDL Ireland
- Employees
- AACT N/A
- AVDL N/A
- Industry
- AACT
- AVDL Biotechnology: Pharmaceutical Preparations
- Sector
- AACT
- AVDL Health Care
- Exchange
- AACT Nasdaq
- AVDL Nasdaq
- Market Cap
- AACT 697.5M
- AVDL 784.6M
- IPO Year
- AACT 2023
- AVDL 1996
- Fundamental
- Price
- AACT $11.30
- AVDL $9.18
- Analyst Decision
- AACT
- AVDL Strong Buy
- Analyst Count
- AACT 0
- AVDL 6
- Target Price
- AACT N/A
- AVDL $18.17
- AVG Volume (30 Days)
- AACT 644.3K
- AVDL 1.7M
- Earning Date
- AACT 01-01-0001
- AVDL 08-07-2025
- Dividend Yield
- AACT N/A
- AVDL N/A
- EPS Growth
- AACT N/A
- AVDL N/A
- EPS
- AACT 0.36
- AVDL N/A
- Revenue
- AACT N/A
- AVDL $194,450,000.00
- Revenue This Year
- AACT N/A
- AVDL $56.88
- Revenue Next Year
- AACT N/A
- AVDL $29.81
- P/E Ratio
- AACT $31.27
- AVDL N/A
- Revenue Growth
- AACT N/A
- AVDL 252.64
- 52 Week Low
- AACT $10.65
- AVDL $6.38
- 52 Week High
- AACT $11.62
- AVDL $17.30
- Technical
- Relative Strength Index (RSI)
- AACT 45.02
- AVDL 47.63
- Support Level
- AACT $11.27
- AVDL $9.10
- Resistance Level
- AACT $11.32
- AVDL $9.76
- Average True Range (ATR)
- AACT 0.06
- AVDL 0.47
- MACD
- AACT -0.02
- AVDL -0.08
- Stochastic Oscillator
- AACT 14.67
- AVDL 14.29
About AACT Ares Acquisition Corporation II
Ares Acquisition Corp II is a blank check company.
About AVDL Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.